Latest News

Germany lagging behind in stem cell research

Neural stem cell. Confocal microscopy image illustrating long-range organization for neurons (green) and nuclei (blue) within a developing neural construct. © University of Wisconsin, Photo: Michael Schwartz.


by tg

A new analysis comparing the amount of funding invested into stem cell research clearly demonstrates declining investment in Germany. In contrast, the US, the UK, Sweden and Japan have increased their investments into the future field.

According to a White Paper from experts of the German Stem Cell Network (GSCN), investments into stem cell research in Germany initially increased from €58.8m in 2009 to €71.3m in 2011 but then permanently decreased to €54.9m by 2014. In contrast, the UK government almost doubled the amount of money into stem cell research from €82.4m in the fiscal year 2010/11 to €169.2m in 2014/15. Whilst investments of the Japanese funding bodies remained constant (€65.1m) from 2009-2012, they rose to €91.2m in 2014 due to the new focus of government investment into applications of induced pluripotent cells (iPSCs).

Most funding, however, is available in the US: the NIH has increased its annual budget for stem cell research from €1,070m in 2011 to €1.400m in 2015. However, funding of the state of New York and the Californian CIRM added €40.5m and €270m annually from 2011-2015 to that amount, respectively.

The GSCN said that Germany ranked last in funding with €0.68/citizen behind Japan (0.72), Sweden (1.02), the UK (2.62), and the US (4.36). The European Federation of Pharmaceutical Industry Associations (EFPIA) and the European Commission have put a focus on creating stem cell resources for secondary drug screening within the Innovative Medicines Initiative. They underline the need for improved funding to exploit the potential of stem cells in drug screening and regenerative medicine.

Orchard Therapeutics raise US-$150m

In April, Orchard expanded its portfolio of gene therapies against primary immune deficiencies and inherited metabolic disorders with...

Epigenetic biomarkers predict immunotherapy success

At the ASH Summit on Emerging Immunotherapies for Hematologic Diseases, the company presented data on prognostic blood-based stratifications of...

EU approves Shire's van Willebrand factor

The European Commission granted EU approval for Veyvondi to prevent bleeding events and  surgical bleeding in desmopressin-refractive adults...

Artios Pharma raise €85m in Series B round

Existing investors Arix Bioscience, SV Health Investors, M Ventures, IP Group and AbbVie Ventures also participated in the oversubscribed Series B...

Arix Bioscience acquires 11% stake in Phamaxis Ltd.

London-based Arix Bioscience announced it has acquired an 11 % interest in Pharmaxis in a two tranche placement contributing £8m, while £5.4...

Boehringer Ingelheim starts gene therapy collaboration for cystic fibrosis

Under the deal, Boehringer Ingelheim acquires an option to licence IP from Imperial Innovations, the tech transfer arm of Imperial College London,...

New lupus target unraveled

Lupus affects approximately 1.5 million US-Americans. One of the most common lupus symptoms is photosensitivity, which occurs when the skin becomes...